About Decheng Capital

Decheng Capital is a leading investment firm that provides capital and strategic support to early stage life science companies with revolutionary technologies and growth stage healthcare companies with strong market presence. Located in Shanghai and Silicon Valley, we are a group of dedicated professionals with complementary expertise who have outstanding track records of building highly successful companies globally. Founded in 2012, Decheng continues to capitalize on a historic opportunity in the rapid growth of healthcare industry as well as breakthroughs in life science research. With over $1 billion in capital under management and support from some of the most prestigious LPs in the world, Decheng is poised to deliver superior returns for our investors and create value for our entrepreneur partners.

News

November 4, 2019
SinoMed, a Medical Device Company, Stages $50 Million IPO on the Shanghai STAR Exchange

August 29, 2019
Sema4 Lands New Investors, Continues to Expand

August 12, 2019
Atricure Offers $300M for SentreHeart

July 17, 2019
BeyondSpring Announces Pricing of Public Offering Ordinary Shares

June 26, 2019
Adaptive Biotechnologies Announces Pricing of Initial Public Offering

June 5, 2019
EpimAb Biotherapeutics Raises $74 million in Series B Financing

May 30, 2019
Adaptive Biotechnologies files for $230M IPO, banking on big Microsoft and Genentech deals

May 17, 2019
Hangzhou's AnHeart Completes $14.6 Million A Funding

February 14, 2019
Bioheng Closes $15 Million Funding for CAR-T Products

January 16, 2019
Alpine Immune Sciences Announces $25 Million Private Placement

January 3, 2019
Mindstrong Health Expands Series B Financing with $31M Investment